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Summary 
We investigated the in vivo effects of cyclosporin A (CsA) on the production of interleukin (IL) 
10,  a cytokine with  major immunosuppressive properties.  To elicit I1:10  production  in vivo, 
BALB/c mice were injected either with the anti-mouse CD3  145-2Cll  monoclonal antibody 
(mAb) (25/~g) or with bacterial lipopolysaccharide (LPS)  (20/zg).  A  systemic release  of I1:10 
was observed in both models, IL-10 serum levels reaching  1.60  •  0.32 U/ml (mean  •  SEM) 
and 0.67  +  0.09 U/ml 6 h after injection of 145-2Cll mAb and LPS, respectively. Experiments 
in nude mice indicated that  T  cells are involved in the induction  of IL-10 by anti-CD3  mAb, 
but not by LPS.  Pretreatment  with CsA (total dose: 50 mg/kg) before injection of 145-2Cll 
mAb completely prevented the release of II,-10 in serum as well as IL-10 mRNA accumulation 
in spleen cells. In contrast, CsA markedly enhanced LPS-induced I1:10 release (IL-10 serum levels 
at 6 h:  8.31  +  0.43 vs. 0.71  •  0.15 U/ml in mice pretreated with CsA vehicle-control, p  < 
0.001),  as well as I1:10  mRNA accumulation  in spleen.  We conclude that  CsA differentially 
affects I1:10 production in vivo depending on the nature of the eliciting agent. This observation 
might  be relevant  to clinical  settings,  especially in organ  transplantation. 
A 
major property of IL-10 is to inhibit cell-mediated im- 
munity by blocking several functions of APCs, including 
the delivery of accessory signals  to CD4 + Th  cells of the 
THO or TH1 type (1-3). It is therefore anticipated that I1: 
10 might  play an important  regulatory role in the process 
of allograft rejection.  As cyclosporin A  (CsA) is currently 
used in most immunosuppressive protocols in organ trans- 
plantation,  we were interested in determining  the effects of 
this drug  on IL-10 production  in vivo. 
Since  in  vitro  studies  established  that  in  addition  to 
CD4 + cells,  macrophages and B cells also represent poten- 
tial sources of Ibl0 (4-6),  two different stimuli were used 
to induce I1:10 production in mice: the 145-2Cll anti-mouse 
CD3 mAb as a polyclonal T cell activator, and bacterial LPS 
as an activating agent for B cells and macrophages.  In both 
settings,  increased serum levels of II:10, as well as IL-10 mRNA 
accumulation in spleen were observed. These two parameters 
Part of this work was presented at the 14th International  Congress of the 
Transplantation  Society, Paris, 16-21 August 1992. 
were therefore used to study the in vivo modulation of I1:10 
production  by CsA. 
Materials and Methods 
Mice.  6-8-wk-old BALB/c mice and nude mice were obtained 
from the Katholieke Universiteit ofLeuven (Leuven, Belgium) and 
from Olac (Bicester, England),  respectively. 
Agents Injected In Viw  The hamster mAb 145-2Cll directed 
against the mouse CD3 complex (7) was prepared from culture 
supernatants of 145-2Cll hybridoma cells by affinity chromatog- 
raphy over a protein  A-Sepharose column  (Pharmacia, Uppsala, 
Sweden), as previously described (8). Control hamster  Igs were 
purified from normal hamster serum by the same procedure. The 
endotoxin levels of these preparations were <15 pg/ml. CsA and 
its vehicle for parenteral administration were a kind gift of Sandoz 
Ltd. (Basel, Switzerland).  LPS from Escherichia coli was obtained 
from Sigma Chemical Co. (St. Louis, MO). 
ExperimentalPwtocols.  Mice received a single intraperitoneal in- 
jection of either  145-2Cll  mAb (25 #g) or control hamster Igs 
(25/~g), or LPS (20/~g). Blood samples were obtained by retroor- 
bital puncture at 1.5, 6, 12, and 24 h after injection for measure- 
ment of serum II,-10 levels. In separate experiments, mice were killed 
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The effects of CsA on the induction of I1r  by anti-CD3  mAb  E 
or LPS were evaluated by pretreating  mice with two 25-mg/kg  ~"  v  4 
i.p. injections of CsA (or its vehicle alone as control) given 18 and 
3 h before anti-CD3  mAb or LPS challenge. This protocol was  3- 
found previously to prevent the release of Ib4 induced by the  ~ 
145-2Cll mAb (9). 
Determination of ILlO Serum Levels by ELISA.  Serum samples  ~,~ 
were assayed  for ID10 by ELISA (10) using the following anti-mouse 
IL-10 mAbs: SXC1, a rat IgM kindly provided by Dr. T. Mosmann  s  1 
(University of Alberta, Edmonton, Canada), and JES5-2A5, a rat 
IgG1 obtained from Pharmingen (San Diego, CA). Briefly,  96-wdl  -  0 
trays were coated with SXC1 mAb (5 #g/ml in PBS) during a 3-h 
incubation at 37~  Excess protein binding sites were blocked by 
a further incubation with 2% BSA in PBS. Serum samples diluted  5 
in PBS containing 0.5% BSA were then added and incubated over- 
night at 4~  After washing, the JES5-2A5  mAb (50 ng/well)  "~ 
4  was incubated for 2 h at 37~  Bound JES5-2A5  mAb was re- 
vealed by a biotinylated mouse anti-rat IgG1 mAb (Experimental 
Immunology Unit, Universit~ Catholique de Louvain) followed  ~  >  3 
by streptavidin-horseradish peroxidase  conjugate. Results were ex-  J 
pressed in IL-10  U by reference  with a standard curve obtained with  2 
a preparation of  recombinant mouse IIr  (Pharmingen). The lower  ~'~ 
limit of detection of II,10 in this assay  was 0.5 U/ml. For calcula- 
o  1 
tion of mean  +  SEM values, samples below that threshold were  7 
arbitrarily assigned a value of 0.4 U/ml. 
Reverse PCR for IL-IO mRNA.  RNA extraction from mouse  0 
spleen cells using the guanidininm thiocyanate method, prepara- 
tion of  eDNA and PCK for IL.10  and hypoxanthine phosphoribosyl 
transferase (HPRT) were performed by standard procedures (11). 
Briefly, 1/zg of total RNA was incubated 10 min at 65~  with 
1 #g oligo(dT)15 and was further incubated for 60 min at 37~ 
with 120 U RNasin (Promega Corp., Madison, WI), 1 mM dNTPs, 
200 U Moloney murine leukemia virus (Mo-MuLV) reverse tran- 
scriptase, 0.01 mg/ml acetylated BSA, and KT buffer (75 mM KC1, 
3 mM MgClz, 10 mM DTT, 50 mM Tris HCI, pH 8.3) in a final 
volume of 20/~1. PCR was performed using aliquots of  the resulting 
cDNA (equivalent to 50 and 500 ng of total RNA for HPKT and 
IL-10 assays, respectively).  To this was added 0.1 mM dNTPs, 2.5 U 
Taq DNA polymerase, 1/zg of each sense/antisense primer, and 
PCR buffer (1.2 mM MgClz, 50 mM KC1, 0.001% gelatine, 10 
mM Tris HC1, pH 8.3) in a total volume of 25 #1. Primers used have 
been published (2, 12). Reactions were incubated in a DNA thermal 
cycler  (Perkin-Elmer Cetus, Norwalk, CT) for 28 cycles  (denatura- 
tion:  1 min, 93~  annealing: 2 min,  550C; extension: 3 min, 
720C). PCR products were run on a 3% agarose gel and stained 
with ethidium bromide. 
$tatis~aIAnalysis.  Statistical comparisons were made using the 
unpaired Student's t test. In each group, values from all mice were 
included. 
Results 
Release of 11.,10 in Serum after Injection of Anti-CD3  mAb 
or LPS into BALB/c  Micg  Whereas  serum  from normal 
BALB/c mice did not contain detectable II.-10 as assayed by 
ELISA (lower limit of detection: 0.5 U/m1), the injection 
of 25 #g of the anti-CD3 mAb 145-2Cll was followed by 
the appearance of circulating IL-10 (Fig. 1, top). Serum ID10 
was already detected at 1.5 h in three out of right mice (mean 
_+  SEM: 0.70  _+ 0.19 U/ml), peaked at 6 h (mean  _+  SEM: 
1.60 _+ 0.32 U/m1), and returned to near background values 
at 24 h. This release of IL-10 was directly related to the anti- 
Anti-CD3 
￿9  m  | 
0  1 5  6  12  18  24 
TIME (hours) 
LPS 
0  15  6  12  18  24 
TIME (hours) 
Figure 1.  Release  of Ibl0 in serum after  a single  injection  of 145-2Cll 
anti-mouse CD3 mAb or bacterial  LPS in BALB/c mice. (~p): (@) mice 
injected with 25 #g 145-2CI1 mAb; (O) controls injected  with 25/~g 
of control hamster Igs. (Bottom) Mice injected with 25 #g LPS. 
body specificity of the 145-2Cll mAb as it was not observed 
in mice injected with control hamster Igs (Fig.  1, top). 
The injection of LPS (25 #g) into BALB/c  animals was 
also followed by the systemic release of II.-10 (Fig. 1, bottom), 
although ILl0 serum levels were lower than after injection 
of the 145-2Cll mAb. Ibl0 was detectable in serum 1.5 h 
after LPS injection in 8 out of 11 mice (mean  _+  SEM: 0.68 
_+  0.09 U/ml),  and at 6 h  in 7 out of 15 mice (mean  _+ 
SEM: 0.67 +_ 0.9 U/ml). No serum I1.-10 was found at later 
time points. 
CsA Prevents Anti-CD3 mAb-induced Production but Enhances 
LPS-induced 11,10 Production.  The in vivo effects of CsA on 
the  systemic release  of IIr  were investigated in animals 
pretreated with two 25-mg/kg i.p. injections of CsA given 
18 and 3 h before challenge with anti-CD3 mAb or LPS (Fig. 
2).  CsA completely prevented the systemic release  of IL-10 
induced by anti-CD3 mAb as indicated by the lack of detect- 
able serum Ibl0 at all time points studied. As control, mice 
were pretreated with CsA vehicle alone before anti-CD3 mAb 
injection. The 1I.-10 serum levels in these animals were similar 
to those measured in the absence of pretreatment (mean  + 
SEM at 6 h: 1.69  +  0.46 U/ml). In contrast with its inhibi- 
tory effect on anti-CD3 mAb-induced II.-10 production, CsA 
pretreatment led to a major increase in the II-10 serum levels 
measured 6 h after LPS challenge (mean  +  SEM:  8.31  + 
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Effects of CsA pretreatment on the systemic release of IL-10 
induced by anti-CD3 mAb or LPS in BALB/c mice. Mice (n =  5 in each 
group) were pretreated with two 25 mg/kg-i.p, injections of CsA or CsA 
vehicle  before injection  of 25 #g 145-2Cll mAb or 20/xg LPS. Ibl0 serum 
levels were measured 6 h after challenge, and data of all mice are presented 
as mean  +_  SEM. 
0.43 U/ml vs. 0.71  + 0.15 in mice pretreated with CsA ve- 
hicle alone, iv <  0.001)  (Fig.  2). 
We analyzed whether the effects of CsA on Ibl0 release 
were related to modulation of I1,10 gene expression. No or 
minimal expression of IL-10 mRNA was found in spleens 
of untreated mice or of mice injected with CsA alone (Fig. 
3). Anti-CD3 mAb injection led to a marked accumulation 
of II.-10 mRNA which was almost completely prevented by 
CsA pretreatment (Fig. 3). LPS also led to I1,10 gene induc- 
tion and in this setting CsA pretreatment resulted in a clear 
increase in  IL-10 mtLNA accumulation (Fig.  3). 
LPS but Not A nti-CD3 mA b Induces ILIO Production in Nude 
Mice.  The role of T  cells in II.-10 production induced by 
anti-CD3 mAb or LPS was investigated by challenging nude 
mice with these stimuli. Neither unmanipulated nude mice 
Figure 3.  Effects  of CsA pretreatment  on Ibl0 mRNA expression in 
spleen after injection  of 145-2Cll anti-CD3 mAb or LPS in BALB/c mice 
(same protocol  as in Fig. 2). Spleens were removed 2 h after anti-CD3 
mAb or LPS challenge and analyzed by reverse PCIL for IL-10 mRNA 
expression. Amplification of the housekeeping gene HPlkT was used as 
control. (Lane 1) Control mice injected with saline; (lane 2) CsA alone; 
(lane 3) anti-CD3 mAb; (lane 4) anti-CD3 mAb after CsA pretreatment; 
(lane 5) LPS; lane 6: LPS after CsA pretreatment. 
Figure 4.  IL-10  mlLNA expression in spleens of nude mice after injec- 
tion of 145-2Cll anti-CD3 mAb or LPS. Spleens were removed 2 h after 
anti-CD3 mAb or LPS challenge and analyzed by reverse PCR for IL-10 
and HPRT mRNA expression. (Lane I) Control mice injected with sa- 
line; (lane 2) anti-CD3 mAb; (lane 3) LPS. 
nor  nude  mice  injected  with  anti-CD3  mAb  displayed 
significant I1,10 gene transcription (Fig. 4). I1,10 also remained 
undetectable in their serum at all time points. On the other 
hand, as in BALB/c mice, LPS injection led to I1,10 mRNA 
accumulation (Fig. 4) and induced a systemic release of IL-10 
(mean  _+  SEM at 6 h: 0.63  _+  0.10  U/ml, n  =  5),  which 
was further increased by CsA pretreatment (mean  _+  SEM 
at 6  h:  4.82  +  1.35  U/ml,  n  -  5, p  <  0.05  as compared 
with LPS  alone). 
Discussion 
The first observation of this study is that both anti-CD3 
mAb and LPS  induce the release  of immunoreactive I1,10 
in the bloodstream of normal mice. The range of II.-10 serum 
levels in both settings was quite large, with some samples 
remaining below the detection limit.  Such wide dispersion 
of cytokine serum levels has been previously observed in similar 
models (13,  14).  It is likely that the cell types involved in 
II.-10 production after injection of anti-CD3  mAb or LPS 
are different. Indeed, experiments in nude mice established 
that T cells are required for anti-CD3 mAb-induced but not 
for LPS-induced II,10 production. As previously demonstrated 
for IL-2, IFN-% and I1,4 mtkNAs (15), we might thus as- 
sume that T cells are the major source of II.10 after injection 
of anti-CD3 mAb. Along this line, it was recently shown 
that the CD4 + cell population was the cell type in which 
I1.10 mRNA accumulates after injection of anti-mouse IgD 
mAb (16).  As far as LPS-induced II.-10 production is con- 
cerned, both macrophages and B  cells,  especially Ly-1 + B 
cells, might be involved (5, 6). Whatever its precise cell source, 
I1,10 might be responsible for some of the immune distur- 
bances observed after injection of anti-CD3  mAb or LPS. 
First, the long-lasting immunosuppressive effects of anti-CD3 
mAbs which have been observed both in experimental and 
clinical transplantation (17,  18) could be related, at least in 
part,  to  the production of I1,10.  The immunosuppression 
observed after LPS injection (19, 20)  could also represent a 
consequence of I1,10  production.  Experiments using neu- 
tralizing anti-I1,10 mAb or mice made IL-10-deficient by gene 
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immunosuppression  induced by anti-CD3  mAb and LPS. 
The  main  findings  reported  in  this  paper  concern  the 
differential effects of CsA on the production of IL-10 induced 
by anti-CD3 mAb or LPS. Although it has been well estab- 
lished that CsA inhibits in vitro and in vivo the transcription 
of several cytokine genes in mouse T  cells  including  II.-2, 
IFN-'},,  and II,-4 genes (9, 21, 22), it was recently reported 
that  the drug does not affect the production of Ibl0 by a 
TH2 clone (23).  The experiments  described herein  clearly 
establish that CsA blocks the systemic release of IL-10, as well 
as II--10 gene expression induced by anti-CD3 mAb in vivo. 
In contrast, CsA pretreatment in the LPS model resulted in 
the superinduction of IL-10 gene expression and in a dramatic 
enhancement  in the systemic release  of IL-10. Similar gene 
superinduction by CsA has been previously reported for TGF-/~ 
in human T cells (24), for IL-6 in human PBMCs (25), and 
for the Ly-6E surface antigen  in the T  cell lymphoma-de- 
rived YAC-1 cell line (26). Mechanisms proposed to explain 
CsA-mediated cytokine gene superinduction include the in- 
hibition of the production of nuclear factors binding to nega- 
tive regulatory sequences of corresponding gene or the lack 
of inhibition  of regulatory proteins  that promote cytokine 
gene expression (24, 26). Our experiments in nude mice in- 
dicate that  the enhancement  by CsA of LPS-induced IL-10 
gene expression and Ibl0 production  does not  depend on 
the action of the drug on T cells and could therefore be related 
to a direct effect on Ibl0-producing  cells. 
The in vivo effects of CsA on IL-10 production might be 
relevant to clinical  settings where CsA is used to induce im- 
munosuppression, such as in organ transplantation  or in au- 
toimmune  diseases.  Administration  of CsA  in  transplant 
recipients receiving the OKT3 mAb has been recommended 
to reduce the antibody response to the mAb.  However, by 
blocking OKT3-induced Ibl0 production,  CsA might also 
inhibit an important pathway of immunosuppression.  In pa- 
tients developing endotoxemia under CsA therapy,  the en- 
hanced II~10 production might be beneficial by reducing the 
release of TNF-ot and IL-1 (27), but detrimental by accentu- 
ating  the Th  cell defects induced by LPS. 
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